Effects of zonisamide on tardive dyskinesia: A preliminary open-label trial

Journal of the Neurological Sciences

Volumn 315, Issue 1-2, 2012, Pages 137-140

  Iwata, Yusuke ^a,b   Irie, Sachiko ^b,c   Uchida, Hiroyuki ^a,d   Suzuki, Takefumi ^a,e   Watanabe, Koichiro ^a   Iwashita, Satoru ^b   Mimura, Masaru ^a  

^a KEIO UNIVERSITY   (Japan)

^b Sakuragaoka Memorial Hospital   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^e Inokashira Hospital   (Japan)

Author keywords

Antiepileptic drug; Free radicals; Parkinsonism; Tardive dyskinesia; Treatment; Zonisamide

Indexed keywords

BIPERIDEN; PEROSPIRONE; QUETIAPINE; RISPERIDONE; ZONISAMIDE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; AGED; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; FEMALE; HUMAN; MALE; MENTAL DEFICIENCY; PRIORITY JOURNAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; FEMALE; HUMANS; ISOXAZOLES; MALE; MOVEMENT DISORDERS; TREATMENT OUTCOME;

EID: 84862779333     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2011.12.010     Document Type: Article

References (41)

1. Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry 2008;21:151-6. (Pubitemid 351339869)
2. Leon De. The effect of atypical versus typical antipsychotics on tardive dyskinesia: a naturalistic study. Eur Arch Psychiatry Clin Neurosci 2007;257:169-72.
3. Woods SW, Morgenstern H, Saksa JR, Walsh BC, Sullivan MC, Money R, et al. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study. J Clin Psychiatry 2010;71:463-74.
4. Suzuki T, Uchida H, Watanabe K, Kashima H. Treating a schizophrenic patient with severe tardive dystonia without antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1141-2. (Pubitemid 46810106)
5. Zareba G. Zonisamide: review of its use in epilepsy therapy. Drugs Today 2005;41: 589-97. (Pubitemid 41810474)
6. Murata M, Hasegawa K, Kanazawa I. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 2007;68:45-50. (Pubitemid 46058551)
7. Inanaga K, Nishi S, Kawasaki K. Zonisamide affords a considerable relief to tardive dyskinesia. Chikusuikai Sinkei Johou Kenkyujo Chikusuikai Byoin Nempou 2007;25:37-41 (in Japanese).
8. International classification of diseases: 10th revision (ICD-10). Department of Health and Human Services. 1-4 www.cdc.gov/nchs/icd9.htm 2001.
9. Schooler NR, Kane JM. Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982;39:486-7. (Pubitemid 12152819)
10. Guy W. ECDEU assessment manual for psychopharmacology. Revised. Washington D.C.: Public Health Service, US Government Printing Office; 1976. p. 534-7.
11. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965;52:203-23.
12. Inagaki A, Inada T. Dai 18 kai 2006 nendoban kouseisinbyouyaku toukakansan. Rinsyou Seisin Yakuri 2006;7:147-51 (in Japanese).
13. Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry 2000;61:5-9. (Pubitemid 30158596)
14. Liou YJ,Wang YC, Chen JY, Bai YM, Lin CC, LiaoDL, et al. Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia. Psychiatry Res 2007;153:271-5.
15. Kulkarni SK. PS Naidu. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today 2003;39:19-49.
16. Factor SA, Leffler JB, Murray CF. Drug-induced movement disorders: a clinical review. Access. http://cme.medscape.com/viewarticle/586881 2009 This is also an updated review regarding TD.
17. Brasic JR, Bronson B. Tardive dyskinesia. Access http://emedicine. medscape.com/article/1151826-overview 2010 This is an updated review regarding TD.
18. Vaddadi K, Hakansson K, Clifford J, Waddington J. Tardive dyskinesia and essential fatty acids. Int Rev Psychiatry 2006;18:133-43. (Pubitemid 43791676)
19. Bishnoi M, Chopra K, Kulkarni SK. Possible anti-oxidant and neuroprotective mechanisms of zolpidem in attenuating typical anti-psychotic-induced orofacial dyskinesia: a biochemical and neurochemical study. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1130-8. (Pubitemid 46810111)
20. Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003;17:47-62. (Pubitemid 36044348)
21. Lohr JB. Oxygen radicals and neuropsychiatric illness. Some speculations. Arch Gen Psychiatry 1991;48:1097-106.
22. Lohr JB, Browning JA. Free radical involvement in neuropsychiatric illnesses. Psychopharmacol Bull 1995;31:159-65.
23. Halliwell B, Gutteridge JM. The importance of free radicals and catalytic metal ions in human diseases. Mol Aspects Med 1985;8:89-193. (Pubitemid 16224567)
24. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993;262:689-95. (Pubitemid 23350687)
25. Elkashef AM, Wyatt RJ. Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophr Bull 1999;25:731-40. (Pubitemid 30013555)
26. Cadet JL, Perumal AS. Chronic treatment with prolixin causes oxidative stress in rat brain. Biol Psychiatry 1990;28:738-40. (Pubitemid 20333635)
27. Lohr JB, Kuczenski R, Bracha HS, Moir M, Jeste DV. Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol Psychiatry 1990;28:535-9. (Pubitemid 20298448)
28. Peet M, Laugharne J, Rangarajan N, Reynolds GP. Tardive dyskinesia, lipid peroxidation, and sustained amelioration with vitamin E treatment. Int Clin Psychopharmacol 1993;8:151-3. (Pubitemid 23294920)
29. Brown K, Reid A,White T, Henderson T, Hukin S, Johnstone C, et al. Vitamin E, lipids, and lipid peroxidation products in tardive dyskinesia. Biol Psychiatry 1998;43:863-7. (Pubitemid 28288363)
30. Lerner V, Miodownik C, Kaptsan A, Bersudsky Y, Libov I, Sela BA, et al. Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study. J Clin Psychiatry 2007;68:1648-54. (Pubitemid 350247493)
31. Kothare SV, Kaleyias J. Zonisamide: review of pharmacology, clinical efficacy, tolerability, and safety. Expert Opin Drug Metab Toxicol 2008;4:493-506. (Pubitemid 351728521)
32. Rosler TW, Arias-Carrion O, Hoglinger GU. Zonisamide: aspects in neuroprotection. Exp Neurol 2010;224:336-9.
33. Mori A, Noda Y, Packer L. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res 1998;30:153-8. (Pubitemid 28198243)
34. Noda Y, Mori A, Packer L. Zonisamide inhibits nitric oxide synthase activity induced by N-methyl-D-aspartate and buthionine sulfoximine in the rat hippocampus. Res Commun Mol Pathol Pharmacol 1999;105:23-33. (Pubitemid 30398259)
35. Komatsu M, Hiramatsu M, Willmore LJ. Zonisamide reduces the increase in 8-hydroxy-2′-deoxyguanosine levels formed during iron-induced epileptogenesis in the brains of rats. Epilepsia 2000;41:1091-4.
36. Yamamura S, Ohoyama K, Nagase H, Okada M. Zonisamide enhances delta receptor-associated neurotransmitter release in striato-pallidal pathway. Neuropharmacology 2009;57:322-31.
37. Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry 1990;147:445-51. (Pubitemid 20107108)
38. Howland RH. Drug therapies for tardive dyskinesia: part 1. J Psychosoc Nurs Ment Health Serv 2011;49:13-6.
39. Okada M, Kaneko S, Hirano T, Mizuno K, Kondo T, Otani K, et al. Effects of zonisamide on dopaminergic system. Epilepsy Res 1995;22:193-205.
40. Gluck MR, Santana LA, Granson H, Yahr MD. Novel dopamine releasing response of an anti-convulsant agent with possible anti-Parkinson's activity. J Neural Transm 2004;111:713-24. (Pubitemid 38716550)
41. Murata M. Novel therapeutic effects of the anti-convulsant, zonisamide, on Parkinson's disease. Curr Pharm Des 2004;10:687-93. (Pubitemid 38292396)